FEASIBILITY AND SAFETY OF VENETOCLAX–OBINUTUZUMAB IN FIT AND UNFIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: ANALYSIS OF POOLED CLL13 AND CLL14 TRIALS AND AN ITALIAN CLINICAL PRACTICE COHORT (SIE 2026) - Oct 6, 2026 - Abstract #DP026; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "During C1-2, tumor lysis syndrome was reported in 6.6% of CT and in 5.9% of CP pts, and infusion-related reac- tions in 48.6% and 36.9%, respectively.In CP, fixed-duration VO was feasible across fitness groups, achieving high treat- ment completion rates and dose intensities. Despite more systematic reporting in CT and shorter follow-up in CP, out- comes in CP were in line with those observed in CT and sup- port the use VO as a frontline treatment in CP."
Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • IGH
|
|
A. Zappaterra1; S. Robrecht2; A. Giza2; A. Galitzia3; O. Al-Sawaf2; M. Deodato1; A. Noto1; L. Appio4; L. Laurenti5; M. Lucignano6; J. Olivieri7; C. Patti8; A. Sanna9; L. Schiattone10; E. Tausch11; M. Levin12; C. Da Cunha-Bang13; S. Stilgenbauer11; A. P. Kater14; C. U. Niemann13; M. Hallek2; A. Tedeschi1; K. Fischer2; B. Eichhorst2; A. M. Frustaci1; M. Fürstenau2
|